503A vs 503B: How Compounding Pharmacies Are Regulated

503A vs 503B names the two sections of the Federal Food, Drug, and Cosmetic Act that govern drug compounding. On the FDA's chart of compounding provisions, section 503A covers a licensed pharmacist in a state-licensed pharmacy or a licensed physician, and section 503B covers a registered outsourcing facility. What the two share matters more than what divides them: according to the FDA, compounded drugs are not FDA-approved, whichever section applies.

This explainer is general information about drug regulation, not medical or legal advice. It names no seller and does not tell anyone to take, dose or source a drug. Every description of the two sections below is taken from the FDA's own compounding pages, which are linked where each point is made and listed at the end. If you want the approval question on its own, compounding vs FDA approval covers it in more depth, and the peptide glossary defines the recurring terms.

Who each section covers

The FDA's chart of FD&C Act provisions that apply to human drug compounding sets the two sections side by side. On the agency's description, section 503A applies to compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered with FDA as an outsourcing facility. Section 503B applies to compounding within an outsourcing facility, by or under the direct supervision of a licensed pharmacist; the same chart notes that an outsourcing facility is not required to be a licensed pharmacy.

The FDA's page of information for outsourcing facilities gives the statutory definition in plain terms: an outsourcing facility is a facility at one geographic location or address that is engaged in compounding sterile drugs, has elected to register as an outsourcing facility, and complies with all of the requirements of section 503B. Registration is a choice a compounder makes, and it changes which set of rules the compounder works under.

Prescriptions: the clearest practical difference

The single condition most readers will notice is the prescription requirement. Under section 503A, the FDA provisions chart says compounding must be based on the receipt of a valid prescription for an identified individual patient. For section 503B, the same FDA chart says an outsourcing facility may or may not obtain prescriptions for identified individual patients.

That difference explains why the two tracks are usually described in different terms. A 503A pharmacy is working from an individual prescription. A 503B outsourcing facility can compound without one for each patient, under the separate conditions section 503B attaches. Neither arrangement says anything about whether the drug itself has been shown to work; it describes how the compounding is authorised.

Who inspects whom

The FDA's compounding questions and answers page sets out the oversight split. On that page, the agency says state boards of pharmacy generally have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities, while the FDA conducts surveillance and for-cause inspections of those pharmacies. Facilities that register as outsourcing facilities under section 503B, the same page says, are primarily overseen by the FDA and inspected on a risk-based schedule.

The questions-and-answers page adds that drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements, and that other federal law, including the provisions on insanitary conditions, applies wherever compounding happens. The FDA's outsourcing-facility page puts the exemption precisely: drugs compounded by an outsourcing facility can qualify for exemptions from FDA approval requirements and from labeling with adequate directions for use, but not from CGMP requirements.

Neither track is FDA approval

This is the point the 503A vs 503B split most often gets confused with. The FDA states on its questions-and-answers page that compounded drugs are not FDA-approved. Its outsourcing-facility page describes the 503B route as an exemption from approval requirements, not a form of approval. A facility's registration, inspection schedule and manufacturing standard describe how a drug is made and who checks the facility. They are not a finding that the drug is safe or effective for any use.

Approval is a separate process. The FDA's overview of the drug development and approval process describes the premarket review a new drug goes through before it can be marketed as approved. A compounding track answers a permission question: may this professional or facility lawfully prepare this drug, and under which conditions? Approval answers an evidence question: has a drug been shown to be safe and effective for its intended use? Keeping those two questions apart is the most useful thing a reader can do with this topic.

Why this comes up so often with peptides

Peptide products turn up in compounding discussions constantly, which is why peptidesmedia covers the regulatory beat around them. Knowing which section a compounder operates under tells you which oversight regime is supposed to apply to how a preparation was made. It does not tell you whether the substance is safe or effective for any purpose; the FDA's compounding questions and answers say compounded drugs are not FDA-approved. Our FDA status tracker records the regulatory position of specific compounds with dates, and our regulatory news hub follows changes as they happen.

For outsourcing facilities specifically, the FDA publishes a list of registered outsourcing facilities. That list is the place to check whether a facility describing itself as 503B is actually registered, rather than relying on how the facility describes itself.

How to read a 503A or 503B claim

A few habits make these labels easier to interpret. None of them require reading the statute yourself.

• Ask which question is being answered. A statement that something may be compounded is a permission statement. A statement that a drug is approved is an evidence statement. Only the second is about whether the drug works.
• Go to the FDA chart for the conditions. The FDA's provisions chart is where the conditions for each section are listed, and the agency updates it. Use it rather than a paraphrase, including this one.
• Check a 503B claim against the registry. The FDA's registered outsourcing facilities list is the public record of who has registered.
• Read "503B" as an exemption, not an endorsement. On the FDA's own wording on its outsourcing-facility page, outsourcing-facility drugs can qualify for exemptions from approval requirements. An exemption is not an approval.
• Take individual questions to a licensed clinician or pharmacist. Whether a particular preparation is appropriate for a particular person is a clinical question, and this article does not answer it.

Common questions

Is a compounded drug the same as an FDA-approved drug?

No. The FDA's questions-and-answers page states that compounded drugs are not FDA-approved. A preparation can be lawfully compounded under section 503A or section 503B and still not be FDA-approved, because compounding and approval are separate legal questions.

Does 503B mean the FDA has checked the drug?

It means the FDA primarily oversees the facility and inspects it on a risk-based schedule, and that the facility's drugs are subject to CGMP requirements, according to the FDA's compounding questions and answers and its outsourcing-facility page. It does not mean the agency has reviewed the drug for safety or effectiveness the way it reviews an approved drug.

Where are the actual rules?

The FDA's provisions chart and its compounding questions-and-answers page are the current, authoritative summaries, and both point to the underlying sections of the FD&C Act. Treat any secondhand summary, this one included, as a starting point.

The short version

Section 503A is the pharmacy-and-physician track, built around individual prescriptions; section 503B is the registered outsourcing-facility track. The conditions for each are on the FDA provisions chart, and the oversight split is on the FDA questions-and-answers page. Neither track is FDA approval. Check those pages, which the FDA keeps current, before acting on anything you read here.

Sources

• U.S. Food and Drug Administration: FD&C Act Provisions That Apply to Human Drug Compounding
• U.S. Food and Drug Administration: Compounding and the FDA: Questions and Answers
• U.S. Food and Drug Administration: Information for Outsourcing Facilities
• U.S. Food and Drug Administration: Registered Outsourcing Facilities
• U.S. Food and Drug Administration: Development & Approval Process | Drugs

Editorial note: This article is general information about drug regulation, not medical or legal advice. It recommends nothing and makes no claim that any compounded preparation is safe or effective for any person. Regulatory conditions can change; check the current FDA pages above before relying on any of it.